Pharmaceutical
-
Ultragenyx Pharmaceutical Class Action Lawsuit: April 6, 2026 Deadline to File Claims – Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC
Ultragenyx Pharmaceutical Inc. faces a class action lawsuit with an April 6, 2026 deadline for claimants. The suit involves allegations regarding the company’s business practices and disclosures, common in the pharmaceutical sector due to complex regulations and market dynamics. Affected parties should consult legal counsel specializing in class action litigation and securities law to understand their rights and ensure timely filing.
-
S&P Raises Teva to ‘BB+’ on Growth Strategy Success, Moody’s Eyes Positive Outlook
Teva Pharmaceutical Industries has received upgraded credit ratings and a positive outlook from S&P and Moody’s. These actions reflect the company’s successful “Pivot to Growth” strategy, evidenced by consistent deleveraging and a return to revenue growth. Strong performance in branded medicines and upcoming biosimilar launches are key drivers, offsetting generics headwinds. This signifies Teva’s progress toward financial health and potentially investment-grade status.
-
Dr. Ashley’s Limited and Impact BioMedical Inc. to Merge Strategically
On June 23, 2025, Dr Ashleys Limited and Impact BioMedical Inc. announced a merger deal. Dr. Ashleys will acquire Impact BioMedical through a reverse merger, creating a new entity listed on the NYSE American. This strategic alliance merges Impact BioMedical’s innovative patents with Dr Ashleys’ resources and global reach, aiming to expedite the development of impactful therapies and expand global market access for biomedical advancements.
